Hye Sook Chon, MD
Gynecologic Oncology · Tampa, FLNPI 1619102563
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,675 of the $28,954 with a category attached, or 85.2%. Eisai Inc. accounts for 67.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $12,100 and has fallen 73.5% since, to $3,212 in 2025.
Across 39 payments — averaging $742.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$20K
- Acrotech Biopharma Inc.$6K
- Merck$2K
- AbbVie$720
- AstraZeneca$559
- Foundation Medicine, Inc.$269
- plus $498 from 4 others
Across 291 payments — averaging $8139.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$917K
- AstraZeneca$717K
- Karyopharm Therapeutics Inc.$302K
- GSK$215K
- Ascendis Pharma Endocrinology Inc$188K
- Seagen Inc.$30K
- plus $360 from 1 others
What the payments were for
- Consulting fees$24,67585%
- Speaking & faculty fees$7503%
- Travel & lodging$1,8816%
- Food & beverage$1,5885%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 18 | $19,508 |
| Acrotech Biopharma Inc. | 5 | $5,864 |
| Merck | 2 | $1,536 |
| AbbVie | 2 | $720 |
| AstraZeneca | 2 | $559 |
| Foundation Medicine, Inc. | 2 | $269 |
| Tesaro, Inc. | 2 | $143 |
| GSK | 3 | $133 |
| Boston Scientific | 2 | $123 |
| Astellas Pharma Global Development | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$19,229
- RYZNEUTA$5,864
- LYNPARZA$525
- FOUNDATIONONE$173
- FOUNDATIONONE CDX$173
- FOUNDATIONONE HEME$173
- FOUNDATIONONE LIQUID$173
- FOUNDATIONFOCUS$173
- Elahere$120
- ZEJULA$107
How this compares
$28,954 in reported general payments places this provider in the 75th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Tampa
- Robert WenhamTampa$89K
- Jing-Yi ChernTampa$44K
- Vaagn AndikyanTampa$10K
- Thomas RutherfordTampa$6K
- Monica AvilaTampa$5K
- Adrian KohutTampa$5K
- Mitchel HoffmanTampa$5K
- Maya YasukawaTampa$3K
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.